UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation Additionally, two posters on data

READ MORE

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Zug, Switzerland:    Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and

READ MORE